Lilly to invest $4.5 bln on new Indiana facility
Adds CEO comment in paragraph 3, details in paragraph 4 and background in paragraph 5
Oct 2 (Reuters) -U.S. drugmaker Eli Lilly LLY.N said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and drug development in Indiana.
The center, Lilly Medicine Foundry, will focus on researching new ways of producing medicines and scaling up the production of drugs used in its clinical trials.
Lilly's CEO David Ricks said the facility, which will be located in Lebanon, Indiana and open in late 2027, could increase output by 400% and help in quicker delivery of medicines to patients.
Once fully operational, the facility is expected to add 400 full-time jobs, including engineers, scientists, operations personnel and lab technicians.
The new facility adds to previous manufacturing commitments by the company in Lebanon, which include a $5.3 billion investment to manufacture active pharmaceutical ingredients for its latest diabetes and obesity medicines.
It takes the company's total capital commitment in the United States since 2020 to more than $23 billion.
Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru; Editing by Shinjini Ganguli and Krishna Chandra Eluri
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
